Reneo Pharmaceuticals – Addressing The Unmet Need of Rare Genetic Mitochondrial Disease
Gregory Flesher is the CEO of Reneo Pharmaceuticals, a company that is developing therapies for rare genetic mitochondrial diseases. REN001, the company's lead candidate, is currently being tested in a Phase 2b clinical trial for Primary Mitochondrial Myopathies. Flesher discusses the progress of REN001 and the future plans for Reneo Pharmaceuticals.
Reneo Pharmaceuticals, led by CEO Gregory Flesher, is tackling the significant unmet need of developing therapies for patients with rare genetic mitochondrial diseases. The company's main candidate, REN001, is currently being investigated in the Phase 2b STRIDE clinical trial for Primary Mitochondrial Myopathies. Flesher talks about the ongoing development of REN001 and the future plans for the company.
Gregory Flesher is CEO of Reneo Pharmaceuticals. The company is developing therapies for rare genetic diseases. Its main candidate, REN001, is being tested in a Phase 2b clinical trial. Flesher discusses the progress of REN001 and the company's future plans.
#ReneoPharmaceuticals
Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company developing therapies for rare genetic mitochondrial diseases. With over 25 years of experience in the biopharmaceutical industry, Greg has a track record of successfully leading development programs resulting in product approvals and commercial launches. Prior to Reneo, he served as CEO of Novus Therapeutics and Chief Business Officer of Avanir Pharmaceuticals. Greg holds a B.S. in biology from Purdue University and has studied biochemistry and molecular biology at Indiana University School of Medicine.
Watch video Reneo Pharmaceuticals – Addressing The Unmet Need of Rare Genetic Mitochondrial Disease online without registration, duration hours minute second in high quality. This video was added by user HPR 06 January 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 31 once and liked it people.